Rosuvastatin calcium tablets and preparation method thereof
By adding surfactant and chelating agent to rosuvastatin calcium tablets, the dissolution performance in low pH environment is improved, and the problem of insufficient dissolution performance of rosuvastatin calcium tablets in gastric juice is solved, ensuring that eating is done Or the efficacy of patients with faster digestion has achieved higher clinical application effects.
Patent Information
- Application Number
- CN202310984586.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-07
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-08-07
AI Technical Summary
Rosuvastatin calcium tablets have insufficient dissolution performance under low pH environments, which is especially detrimental to patients who eat or digest faster.
Improve tablet formulations by adding suitable excipients such as surfactants and chelating agents, including rosuvastatin calcium, microcrystalline cellulose, lactose, cropovidone, maltitol, hydroxypropyl cellulose, span and EDTA , dry granulation, tableting and coating steps are adopted to improve the dissolution performance in gastric juice.
It significantly improves the dissolution performance of rosuvastatin calcium tablets in low pH environments, especially in simulating the dissolution rate in gastric juice, ensuring the efficacy of the drug in patients with faster eating or digestion, and meeting higher clinical needs.
Smart Images

Figure CN117137876B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of blood lipid regulating drugs and pharmaceutical preparations. Specifically, the present invention provides a rosuvastatin calcium tablet and a preparation method thereof. Background Art
[0002] Rosuvastatin calcium is a selective HMG-CoA reductase inhibitor that can be used to treat hyperlipidemia, such as primary hypercholesterolemia and mixed dyslipidemia. It is a commonly used drug in clinical practice, and tablets and capsules are available on the market from domestic and foreign manufacturers.
[0003] According to current research results, rosuvastatin calcium tablets have good dissolution properties in water, but the dissolution performance deteriorates rapidly as the pH decreases. Although the dissolution performance of the current tablets can meet the needs of most people / situations, there is a risk of insufficient dissolution performance for some patients who eat and digest quickly.
[0004] Therefore, there is still a need to improve the performance of rosuvastatin calcium. Summary of the invention
[0005] To solve the above problems, the applicant tried to develop tablets with improved low pH dissolution performance, and solved this problem by screening suitable excipients and adding surfactants and chelating agents.
[0006] On the one hand, the present application provides a rosuvastatin calcium tablet, which comprises rosuvastatin calcium, microcrystalline cellulose, lactose, crospovidone, hydroxypropyl cellulose, maltitol, a surfactant, silicon dioxide, and magnesium stearate.
[0007] Furthermore, each 1,000 tablets of the rosuvastatin calcium tablets contain 8-12 g of rosuvastatin calcium, 20-80 g of microcrystalline cellulose, 20-60 g of lactose, 1-5 g of crospovidone, 2-8 g of maltitol, 0.5-3 g of hydroxypropyl cellulose, 2-5 g of Span 60, 0.5-5 g of silicon dioxide, and 0.1-1.5 g of magnesium stearate.
[0008] Furthermore, each 1,000 tablets of the rosuvastatin calcium tablets contain 10 g of rosuvastatin calcium, 66.5 g of microcrystalline cellulose, 48.5 g of lactose, 3 g of crospovidone, 4 g of maltitol, 1.5 g of hydroxypropyl cellulose, 2.5 g of Span 60, 3 g of silicon dioxide, and 1 g of magnesium stearate.
[0009] Furthermore, the rosuvastatin calcium tablets also contain 0.5-2 g of EDTA per 1,000 tablets.
[0010] Furthermore, each 1,000 tablets of the rosuvastatin calcium tablets are prepared from 10 g of rosuvastatin calcium, 65.5 g of microcrystalline cellulose, 48.5 g of lactose, 3 g of crospovidone, 4 g of maltitol, 1.5 g of hydroxypropyl cellulose, 2.5 g of Span 60, 1 g of EDTA, 3 g of silicon dioxide, 1 g of magnesium stearate and a coating agent.
[0011] On the other hand, the present application provides a method for preparing the above-mentioned rosuvastatin calcium tablets, comprising dry granulation, tableting and coating steps.
[0012] Furthermore, the preparation method comprises: mixing rosuvastatin calcium, half amount of microcrystalline cellulose, half amount of lactose and maltitol, and dry granulating; passing the dry granulation product through a 24-mesh sieve, adding the remaining ingredients, and mixing evenly; tableting; and coating with Opadry II coating liquid, with the coating weight gain being 1-5%.
[0013] On the other hand, the present application provides the use of the above-mentioned rosuvastatin calcium tablets in the preparation of a drug for treating hyperlipidemia.
[0014] The various raw materials in this application are not limited to specific manufacturers and brands. For example, various film coating agents can be used after appropriate verification.
[0015] The tablets of the present application effectively improve the dissolution performance in gastric juice, and improve the effect of rosuvastatin calcium tablets taken by patients who eat or digest food quickly. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The dissolution rate of tablets with different ratios of Span 60 and EDTA in simulated gastric fluid 2 within 15 minutes. DETAILED DESCRIPTION
[0017] Tablet preparation method:
[0018] The raw material of rosuvastatin calcium comes from Shandong Langnuo, the reference substance of rosuvastatin calcium comes from the China Food and Drug Inspection Institute, and other excipients and reagents are all commonly used domestic or imported types.
[0019] Tablet press: ZP-7B (Guangdong Chendiao);
[0020] Granulator: LG-100 (Changzhou Lima);
[0021] The raw materials (except the surfactant) are sieved through an 80-mesh sieve for later use; rosuvastatin calcium, half of the amount of microcrystalline cellulose, half of the amount of lactose, and maltitol are mixed and dry granulated; the dry granulation product is sieved through a 24-mesh sieve, and the remaining microcrystalline cellulose and lactose, crospovidone, hydroxypropyl cellulose, surfactant, silicon dioxide, magnesium stearate and optional EDTA are added and mixed evenly; tableting (diameter 7 mm); coating with 15% Opadry II coating solution (coating weight gain 3%).
[0022] Dissolution performance test method:
[0023] Rosuvastatin calcium tablets are common oral tablet drugs, and the paddle method is generally used to investigate the dissolution performance.
[0024] The dissolution test was conducted using the Olabo ZRE-6 drug dissolution tester; the medium volume was 900 mL, the rotation speed was 50 rpm, and the temperature was 37 degrees Celsius; after sampling at the predetermined time, the samples were filtered with a 0.5-micron membrane, and the supernatant was taken after centrifugation and tested using HPLC; the sampled samples and the control solution were tested, and the dissolution amount / dissolution rate was calculated using the external standard method.
[0025] The HPLC test used an Agilent 1260 Infinity II liquid chromatography system (with an Agilent Hypersil C18 column); the detection wavelength was 242 nm, the column temperature was 35 degrees Celsius, the mobile phase was 50:50 0.2% triethylamine aqueous solution: acetonitrile, the flow rate was 1 mL / min, and the injection volume was 50 μL.
[0026] In order to more comprehensively reflect the dissolution effect in gastric juice, in addition to the commonly used purified water and 0.1 M hydrochloric acid, two artificial gastric juices were selected as dissolution media according to existing records: artificial gastric juice 1 (8 mL of 10% dilute hydrochloric acid, 2 g of pepsin, fixed to 500 mL) and artificial gastric juice 2 (1 g of sodium chloride, 1.5 g of pepsin, 8 mL of 10% dilute hydrochloric acid, fixed to 500 mL).
[0027] Example 1
[0028] Recipe 1:
[0029] The ingredients of each 1000 tablets are: 10g rosuvastatin calcium, 69g microcrystalline cellulose, 48.5g lactose, 3g crospovidone, 4g maltitol, 1.5g hydroxypropyl cellulose, 3g silicon dioxide, and 1g magnesium stearate.
[0030] Reference substance:
[0031] AstraZeneca
[0032] Toto sunny day
[0033] Table 1 Dissolution performance of formulation 1
[0034] time Purified water 0.1M hydrochloric acid Artificial gastric juice 1 Artificial gastric juice 2 5 minutes 91.2% 68.5% 70.2% 67.6% 10 minutes 95.8% 85.4% 86.2% 87.6% 15 minutes 99.5% 88.9% 90.1% 89.5% 20 minutes 100.1% 91.5% 92.6% 90.9% 30 minutes 100.3% 94.5% 93.8% 93.5%
[0035] Table 2 Dissolution performance
[0036] time Purified water 0.1M hydrochloric acid Artificial gastric juice 1 Artificial gastric juice 2 5 minutes 90.5% 70.3% 71.4% 69.7% 10 minutes 95.3% 83.4% 87.1% 86.6% 15 minutes 98.9% 89.2% 91.5% 90.5% 20 minutes 99.7% 92.5% 93.8% 92.2% 30 minutes 100.5% 93.7% 95.1% 94.2%
[0037] Table 3 Dissolution performance of TuoTou
[0038] time Purified water 0.1M hydrochloric acid Artificial gastric juice 1 Artificial gastric juice 2 5 minutes 92.4% 66.9% 69.2% 70.4% 10 minutes 94.9% 86.2% 87.0% 87.1% 15 minutes 98.7% 89.7% 90.4% 88.9% 20 minutes 99.6% 92.3% 92.5% 91.5% 30 minutes 99.9% 95.2% 92.9% 93.6%
[0039] The results showed that the tablets obtained by dry granulation and tableting of formula 1 can meet the basic requirements in terms of hardness (about 66F / N), friability (about 0.027%) and disintegration time (about 2 minutes), as well as stability and storage. The dissolution ability of the three tablets in aqueous solution is relatively ideal, but the dissolution in 0.1M hydrochloric acid and two artificial gastric juices is relatively slow, which may have adverse effects in actual use, especially when used by people who eat / digest quickly.
[0040] Example 2
[0041] The applicant tried to add a variety of surfactants to the tablets to improve the dissolution performance (the following are representative results, and more screening formulations are not shown due to space reasons)
[0042] Recipe 2:
[0043] The ingredients of each 1000 tablets are: rosuvastatin calcium 10g, microcrystalline cellulose 66.5g, lactose 48.5g, crospovidone 3g, maltitol 4g, hydroxypropyl cellulose 1.5g, Span 60 2.5g, silicon dioxide 3g, magnesium stearate 1g;
[0044] Recipe 3:
[0045] Ingredients per 1000 tablets: rosuvastatin calcium 10g, microcrystalline cellulose 67.5g, lactose 48.5g, crospovidone 3g, maltitol 4g, hydroxypropyl cellulose 1.5g, magnesium lauryl sulfate 1.5g, silicon dioxide 3g, magnesium stearate 1g
[0046] Table 4 Dissolution performance of formulation 2
[0047] time Purified water 0.1M hydrochloric acid Artificial gastric juice 1 Artificial gastric juice 2 5 minutes 93.5% 82.9% 83.5% 73.6% 10 minutes 95.2% 93.8% 92.7% 88.1% 15 minutes 98.8% 97.5% 96.8% 90.2% 20 minutes 99.5% 98.9% 97.6% 92.5% 30 minutes 100.1% 99.3% 98.9% 93.7%
[0048] Table 5 Dissolution performance of formulation 3
[0049] time Purified water 0.1M hydrochloric acid Artificial gastric juice 1 Artificial gastric juice 2 5 minutes 92.9% 78.6% 80.3% 71.6% 10 minutes 94.7% 87.9% 91.2% 86.9% 15 minutes 97.8% 94.5% 93.3% 89.9% 20 minutes 99.8% 96.3% 95.5% 93.2% 30 minutes 100.3% 98.6% 98.1% 95.6%
[0050] The results showed that the dissolution performance of the tablets in acidic solution was indeed significantly improved after adding a suitable surfactant, but the improvement was not significant in artificial gastric juice 2 which was closer to gastric juice (gastric juice has a certain Na and other example strength).
[0051] Example 3
[0052] Try to add chelating agents that are allowed in the pharmacopoeia without affecting the basic efficacy of the drug.
[0053] Recipe 4
[0054] The ingredients of each 1000 tablets are: rosuvastatin calcium 10g, microcrystalline cellulose 66g, lactose 48.5g, crospovidone 3g, maltitol 4g, hydroxypropyl cellulose 1.5g, Span 60 2.5g, EDTA 0.5g, silicon dioxide 3g, magnesium stearate 1g;
[0055] Table 6 Dissolution performance of formulation 4
[0056]
[0057]
[0058] The results showed that the addition of EDTA to chelate some alkali metal ions effectively improved the dissolution performance in artificial gastric juice 2; then the applicant fixed the amount of Span 60 at 2.5g on the basis of formula 4, changed the amount of EDTA (the amount of lactose was increased or decreased accordingly, so that the total weight of 1,000 tablets of raw materials remained at 100g); the dissolution effect of different ratios of Span 60 and EDTA was investigated (represented by the 15-minute dissolution rate in simulated gastric juice 2), and the results were as follows Figure 1 As shown, Span 60 2.5g and EDTA 1g provide the best dissolution effect. On this basis, formula 5 is obtained:
[0059] The ingredients of each 1000 tablets are: rosuvastatin calcium 10g, microcrystalline cellulose 65.5g, lactose 48.5g, crospovidone 3g, maltitol 4g, hydroxypropyl cellulose 1.5g, Span 60 2.5g, EDTA 1g, silicon dioxide 3g, magnesium stearate 1g.
[0060] Preliminary experiments also showed that the tablets of Formula 5 can meet the basic requirements for hardness (about 67.4±2.4F / N), friability (0.025±0.06%) and disintegration time (1 minute 41 seconds±3 seconds) in terms of stability (no isomers were detected and the impurity rate was 0.30% after being stored in the dark, room temperature and 70% humidity for one week; no isomers were detected and the impurity rate was 0.17% after being stored in the blister package at room temperature and away from light for 3 months); more than 97% of the tablets can be dissolved in 4 media within 15 minutes, and about 85% of the tablets can be dissolved in artificial gastric juice 2 within 5 minutes.
Claims
1. A rosuvastatin calcium tablet, characterized in that: Each 1,000 tablets of the rosuvastatin calcium tablets are prepared from 10g of rosuvastatin calcium, 65.5g of microcrystalline cellulose, 48.5g of lactose, 3g of crospovidone, 4g of maltitol, 1.5g of hydroxypropyl cellulose, 2.5g of Span 60, 1g of EDTA, 3g of silicon dioxide, 1g of magnesium stearate, and a coating agent; the preparation method of the rosuvastatin calcium tablets includes dry granulation, tableting, and coating steps.
2. A method for preparing the rosuvastatin calcium tablets according to claim 1: the method comprising: Rosuvastatin calcium, maltitol, half the weight of microcrystalline cellulose, and half the weight of lactose are mixed and dry granulated; the dry granulation product is passed through a 24-mesh sieve, the remaining ingredients are added, and the mixture is uniformly mixed; tablets are compressed; and the tablets are coated with Opadry II coating solution, with the coating weight gain being 1-5%.
3. Use of the rosuvastatin calcium tablets according to claim 1 in the preparation of a medicament for treating hyperlipidemia.
Citation Information
Patent Citations
Rosuvastatin calcium oral composition for increasing dissolution rate and preparation method of composition
CN103877042A
Rosuvastatin calcium tablet and preparation method thereof
CN112451495A
Solubility and stability enchancing pharmaceutical formulation
WO2011019326A2
